Alector, Inc. — Q1 2024 Form 10-Q
Reporting period: Three months ended March 31, 2024. Alector is a clinical-stage biotechnology company developing immuno-neurology therapies. It has no approved products and generated no product-sales revenue; reported revenue comes from collaboration agreements.
Financial performance and liquidity
| Metric | Q1 2024 | Q1 2023 | Change |
|---|---|---|---|
| Collaboration revenue | $15.9 million | $16.5 million | Down $0.7 million |
| Research and development expense | $45.2 million | $51.9 million | Down $6.7 million |
| General and administrative expense | $14.4 million | $14.8 million | Down $0.3 million |
| Operating loss | $43.7 million | $50.1 million | Loss narrowed $6.4 million |
| Other income, net | $7.6 million | $5.2 million | Up $2.5 million |
| Net loss | $36.1 million | $45.9 million | Loss narrowed $9.8 million |
| Basic and diluted loss per share | $0.38 | $0.55 | Improved $0.17 |
| Cash used in operating activities | $61.3 million | $48.5 million | Use increased $12.8 million |
Margins: Operating loss was approximately 275% of collaboration revenue, versus 303% in Q1 2023; net loss was approximately 227% of revenue, versus 277%. These ratios reflect a collaboration-funded, pre-commercial business rather than product gross margins.
Liquidity at March 31, 2024: Cash and cash equivalents were $72.6 million and marketable securities were $489.5 million, totaling $562.1 million. Current assets were $581.4 million and current liabilities $164.9 million, implying a current ratio of approximately 3.5. The company reported no conventional borrowings in the presented balance sheet; operating lease liabilities totaled $37.6 million. Deferred revenue was $277.9 million, and collaboration-partner refund liabilities totaled $94.3 million.
Cash, cash equivalents and restricted cash declined $2.0 million during the quarter to $74.1 million. The company received $71.1 million net from a January public offering of 10.9 million shares at $6.57 per share. Accumulated deficit was $746.2 million; shares outstanding rose from 84.9 million at year-end 2023 to 96.4 million at March 31, 2024.
Material changes and business developments
- Collaboration revenue declined 4% year over year, mainly because less revenue was recognized for latozinemab. Revenue is recognized based on performance under the GSK and AbbVie agreements and may vary with program costs and estimates.
- R&D expense fell about 13%, reflecting prioritization of selected later-stage programs and lower personnel costs. AL002 direct program expense increased to $13.3 million from $11.1 million, while direct expenses for latozinemab, AL101 and other programs declined.
- Other income rose with higher investment yields. Despite the narrower net loss, operating cash use increased, partly due to decreases in deferred revenue, collaboration-partner refund liabilities, and accrued liabilities.
- GSK dosed the first participant in the AL101 Phase 2 PROGRESS-AD trial in February 2024; enrollment was progressing and EU country approvals had been obtained by March. Alector is responsible for funding and sharing development costs up to $140.5 million for this initial trial.
- Latozinemab’s INFRONT-3 Phase 3 trial reached target enrollment in October 2023, with 103 symptomatic and 16 at-risk participants enrolled. The FDA granted Breakthrough Therapy Designation in February 2024. The filing does not provide a new readout date for the trial.
- AL002 Phase 2 INVOKE-2 enrollment was completed at 381 patients in Q3 2023; data were expected in Q4 2024. AbbVie retains an option to take over development for a $250 million payment, but the filing does not indicate that it exercised the option.
Outlook, risks and contingencies
- Management expects the $562.1 million of cash, cash equivalents and marketable securities to fund operations and capital requirements through 2026. This is based on assumptions that may prove inaccurate; the company expects to need substantial additional funding over time and may seek financing opportunistically.
- Management expects expenses to increase as clinical and research programs advance, while noting it cannot reliably estimate the timing or cost of completing development or obtaining approvals. Alector reduced its workforce in 2023 to align resources with priorities.
- Key risks include clinical failure or delays, regulatory uncertainty, competition, reliance on GSK, AbbVie and third-party research and manufacturing providers, and the possibility that capital may not be available on acceptable terms. Additional equity financing could dilute shareholders.
- In AL002’s INVOKE-2 trial, treatment-emergent MRI findings resembling amyloid-related imaging abnormalities (ARIA) were observed. Some serious events occurred, initially among APOE e4/e4 participants; dosing and enrollment of that group were voluntarily discontinued. Serious events also occurred in a small number of participants who were not APOE e4/e4. Earlier MRI monitoring continues under independent monitoring committee oversight.
- The company reported no litigation it believed likely to have a material adverse effect. It disclosed customary indemnification arrangements for which maximum potential payments are not determinable; no liability was recorded.
- Interest-rate sensitivity analysis estimated that an immediate 100-basis-point rate change would alter investment fair value by approximately $2.9 million. Management concluded disclosure controls were effective at a reasonable assurance level and reported no material quarterly change in internal control over financial reporting.
Important facts for investors to verify
- Whether management’s cash runway-through-2026 estimate remains supportable as clinical spending and the AL101 cost-sharing commitment develop.
- INFRONT-3 trial progress, analysis timing and results, and any regulatory implications of the symptomatic-participant analysis.
- AL002 Q4 2024 data timing and safety findings, including the status and management of ARIA-like events.
- PROGRESS-AD enrollment, expected costs borne by Alector, and any changes to the GSK collaboration or its refund-liability estimates.
- Potential dilution and remaining availability under the company’s shelf registration and $125 million at-the-market sales agreement.